- Home
- CAC vs CRGX Comparison
CAC vs CRGX Comparison
Compare CAC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- CRGX
- Stock Information
- Founded
- CAC 1875
- CRGX 2021
- Country
- CAC United States
- CRGX United States
- Employees
- CAC N/A
- CRGX N/A
- Industry
- CAC Major Banks
- CRGX
- Sector
- CAC Finance
- CRGX
- Exchange
- CAC Nasdaq
- CRGX Nasdaq
- Market Cap
- CAC N/A
- CRGX 190.0M
- IPO Year
- CAC 1997
- CRGX 2023
- Fundamental
- Price
- CAC $43.10
- CRGX $4.59
- Analyst Decision
- CAC Hold
- CRGX Hold
- Analyst Count
- CAC 3
- CRGX 7
- Target Price
- CAC $47.33
- CRGX $5.33
- AVG Volume (30 Days)
- CAC 62.5K
- CRGX 1.9M
- Earning Date
- CAC 07-29-2025
- CRGX 08-11-2025
- Dividend Yield
- CAC 3.91%
- CRGX N/A
- EPS Growth
- CAC 2.54
- CRGX N/A
- EPS
- CAC 3.09
- CRGX N/A
- Revenue
- CAC $184,324,000.00
- CRGX N/A
- Revenue This Year
- CAC $40.83
- CRGX $57.81
- Revenue Next Year
- CAC $5.29
- CRGX N/A
- P/E Ratio
- CAC $13.92
- CRGX N/A
- Revenue Growth
- CAC 13.26
- CRGX N/A
- 52 Week Low
- CAC $33.83
- CRGX $3.00
- 52 Week High
- CAC $50.07
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- CAC 70.29
- CRGX 61.56
- Support Level
- CAC $42.85
- CRGX $4.32
- Resistance Level
- CAC $43.78
- CRGX $4.63
- Average True Range (ATR)
- CAC 0.98
- CRGX 0.16
- MACD
- CAC 0.37
- CRGX 0.04
- Stochastic Oscillator
- CAC 95.06
- CRGX 76.44
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.